June 21 (Reuters) - The U.S. Food and Drug Administration has approved Bristol Myers Squibb's combination therapy for treating colorectal cancer patients with a specific gene mutation, the health regulator's website showed on Friday. (Reporting by Christy Santhosh, Unnamalai L and Puyaan Singh in Bengaluru; Editing by Shilpi Majumdar)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
41.85 USD | -1.53% | +2.14% | -18.30% |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-18.30% | 8.62TCr | |
+55.05% | 81TCr | |
+43.62% | 64TCr | |
-7.13% | 35TCr | |
+17.93% | 33TCr | |
+8.44% | 30TCr | |
+16.30% | 25TCr | |
+2.41% | 22TCr | |
+12.47% | 22TCr | |
+8.70% | 17TCr |
- Stock Market
- Equities
- BMY Stock
- News Bristol-Myers Squibb Company
- US FDA approves Bristol Myers' colorectal cancer therapy